Trial · NCT01774487
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 18 of 18
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT >2.5X baseline | Hepatobiliary disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 1 | 8 | 1 |
| other | ALT >2.5X baseline | Hepatobiliary disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 0 | 1 | 0 |
| other | Bc >2.5X baseline | Hepatobiliary disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 0 | 8 | 0 |
| other | Bc >2.5X baseline | Hepatobiliary disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 0 | 1 | 0 |
| other | Platelets <150,000/ul | Blood and lymphatic system disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 3 | 8 | 3 |
| other | Platelets <150,000/ul | Blood and lymphatic system disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 1 | 1 | 1 |
| other | Vomiting | Gastrointestinal disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 2 | 8 | 2 |
| other | Vomiting | Gastrointestinal disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 1 | 1 | 5 |
| other | Stopped medication before 12 week period | Product Issues | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 2 | 8 | 2 |
| other | Stopped medication before 12 week period | Product Issues | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 0 | 1 | 0 |
| serious | Failure to thrive | Gastrointestinal disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 3 | 8 | 5 |
| serious | Failure to thrive | Gastrointestinal disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 1 | 1 | 5 |
| serious | Cholangitis | Hepatobiliary disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 2 | 8 | 3 |
| serious | Cholangitis | Hepatobiliary disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 0 | 1 | 0 |
| serious | Ascites | Hepatobiliary disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 0 | 8 | 0 |
| serious | Ascites | Hepatobiliary disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 1 | 1 | 2 |
| serious | Bile leak | Hepatobiliary disorders | Pentoxifylline - Group 1 (Treatment Starts 3-5 Days After Kasai Portoenterostomy) | 1 | 8 | 1 |
| serious | Bile leak | Hepatobiliary disorders | Pentoxifylline - Group 2 (Patient Diagnosed Too Late for Kasai Portoenterostomy) | 0 | 1 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01774487/events